A. Introduction to ARFID (DSM-V 2013, ICD-11 2019)  

B. Focus of review: epidemiology, presentation, comorbidities, treatment efficacy 

 C. Key features: heterogeneity, drivers (sensory, interest, fear)  

D. Common comorbidities: autism spectrum disorder (ASD)  

E. Promising treatments: family-based therapy (FBT), multimodal interventions  

F. Gaps: lack of large-scale RCTs, long-term data, relapse prevention  

G. Need for longitudinal studies 

A. Rationale  

1. Increasing recognition of ARFID 

2.Variability in prevalence (0.3% to 64%)  

3. Diverse presentations and comorbidities  

4. Current interventions show promise but lack robust evidence  

5. Gaps: longitudinal data, assessment methods, tailored treatment protocols  

B. Professional and Social Significance  

1. Impact on nutrition, growth, psychological health  

2. Societal implications: healthcare costs, early intervention benefits  

3. Clinical implications: importance of evidence-supported treatments  

4. Standardization of diagnostic and outcome assessment tools  

C. Theory Bases  

1. Family systems theory: family influence and caregiver involvement 

  2. Cognitive-behavioral models: targeting drivers like sensitivities and fears  

3. Multimodal approach including FBT for relapse reduction 

  D. Objectives  

1. Explore ARFID presentations  

2. Support role of FBT in treatment  

3. Provide data on FBT's effectiveness in reducing relapse  

E. Research Question - Does inclusion of FBT in multimodal treatment reduce relapse compared to multimodal treatment without FBT? 

A. Eligibility Criteria  

1. Participants aged 0-18, diagnosed per DSM-5  

2. Study types: observational, experimental, peer-reviewed  

3. Focus: epidemiology, presentation, treatment (FBT, CBT, multimodal)  

4. Exclusions: adults, non-ARFID studies  

B. Information Sources - Databases: ProQuest, PsycINFO, Medline, Google Scholar, etc. 

  C. Search Strategy - Keywords: feeding disorders, ARFID, FBT, adolescents, relapse  

D. Selection Process - Screening of ~90 articles; full-text review; final inclusion of 17 studies  

E. Study Selection Diagram - PRISMA flow: identification, screening, eligibility, inclusion  

F. Risk of Bias - Potential biases: convenience samples, heuristic biases, limitations of non-RCT designs 

A. Review of Literature  

1. Variability in prevalence (0.3%–64%)  

2. Presentations driven by sensory sensitivities, interest, fear 

3. High comorbidity with ASD and anxiety 

 4. Treatment approaches 

a. Family-based therapy (FBT): promising pilot data 

b. CBT: exposure-based techniques show effectiveness  

c. Meds: limited evidence  

d. Multimodal strategies: inpatient/outpatient weight stabilization  

5. Outcomes  

a. Early intervention improves short-term outcomes  

b. Long-term relapse data limited  

c. FBT's specific role in relapse reduction underexplored  

B. Synthesis of Findings  

1. ARFID's heterogeneity and complexity 

2. Need for tailored, driver-specific interventions 

3. Evidence suggests benefits of family and CBT approaches 

4. Significant gaps: long-term data, large RCTs, standardized assessments 

A. Critical Analysis  

1. Recognition of ARFID's prevalence and heterogeneity 

  2. Overlap with ASD and other conditions  

3. Treatment evidence: promising but limited by methodological weaknesses  

4. Shortcomings in long-term outcome data and relapse prevention  

B. Gaps in Knowledge 

  1. Longitudinal studies on treatment durability  

2. Impact of FBT within multimodal frameworks  

3. Standardized assessment tools  

4. Driver-specific, personalized interventions  

5. Need for large-scale RCTs  

C. Limitations of Current Evidence 

1. Small samples, case reports, uncontrolled designs 

2. Short follow-up durations  

3. Variability in outcome measures  

D. Procedural Limitations  

1. Retrospective, observational data 

2. Lack of consensus on diagnostic and outcome criteria  

E. Revised Research Question 

1. Does integrating FBT into multimodal treatment with CBT lower relapse compared to without FBT?  

F. Hypotheses for Future RCT - FBT + CBT reduces relapse at 12 months 

A. ARFID is complex and heterogeneous 

B. Multimodal treatments, including FBT, show promise but lack definitive evidence 

C. Further research needed: long-term, large-scale, driver-specific, standardized assessments 

D. Goal: improve sustained recovery and relapse prevention in youth with ARFID